Miles Carroll
Research groups
Miles Carroll
Professor of Emerging Viruses
HOST-PATHOGEN INTERACTIONS OF HIGH CONSEQUENCE EMERGING VIRUSES
Our work centres around high consequence emerging viral infections. Currently, our focus is on Ebola, Lassa fever and SARS-CoV-2. We are interested in host-pathogen interactions, development of anti-virals and recently we have been looking at the IgG response following SARS-CoV-2 infection and/or vaccination in humans and animal models. To further support this work we are using a live virus neutralisation, multiplex immunoassays and novel ACE2 inhibition assay to inform on the ability of serum to neutralise SARS-CoV-2 variants of concern (VOC). We are also interested in the innate response to viral infection, particularly activation and/or evasion of the complement system
Recent publications
CE2 inhibition ELISA is an effective surrogate for SARS-CoV-2 live virus neutralisation
Journal article
Tipton T. et al, (2026), Vaccine, 72, 128123 - 128123
Screening of FDA-approved drugs using a recombinant Cedar virus to improve treatment options for Nipah virus infection.
Journal article
Clayton E. et al, (2026), The Journal of general virology, 107
Current knowledge on the host-pathogen interactions of henipaviruses and novel platforms to enable further characterisation.
Journal article
Hantabal J. et al, (2026), EBioMedicine, 123
Discontinuous EBOV RNA synthesis events in patients with Ebola virus disease and their relationship to viral load and outcome of infection.
Journal article
Dong X. et al, (2025), Journal of virology, 99
Dynamic impact of bivalent COVID-19 vaccine boosters on systemic and mucosal antibody and T cell immunity
Journal article
Kronsteiner B. et al, (2025), Scientific Reports, 15